Pharmacodynamics, pharmacokinetics and biodistribution of recombinant human N-acetylgalactosamine 4-sulfatase after 6months of therapy in cats using different IV infusion durations-Reference-Cited by-同舟云学术

Pharmacodynamics, pharmacokinetics and biodistribution of recombinant human N-acetylgalactosamine 4-sulfatase after 6months of therapy in cats using different IV infusion durations

Published:2016-02 Issue:2 Volume:117 Page:157-163
ISSN:1096-7192
Container-title:Molecular Genetics and Metabolism
language:en
Short-container-title:Molecular Genetics and Metabolism

Author:

Ruane Therese,Haskins Mark,Cheng Alphonsus,Wang Ping,Aguirre Gustavo,Knox Van W. (Rafe),Qi Yulan,Tompkins Troy,O'Neill Charles A.

Funder

BioMarin Pharmaceutical, Inc., Novato, CA

Publisher

Elsevier BV

Subject

Endocrinology,Genetics,Molecular Biology,Biochemistry,Endocrinology, Diabetes and Metabolism

Reference27 articles.

1. Mucopolysaccharidosis VI;Valayannopoulos;Orphanet J. Rare Dis.,2010

2. Naglazyme® (galsulfase) solution for intravenous infusion only, [prescribing information,2005

3. Enzyme replacement therapy in a feline model of Maroteaux–Lamy syndrome;Crawley;J. Clin. Invest.,1996

4. Pharmacokinetic profile of recombinant human N-acetylgalactosamine 4-sulphatase enzyme replacement therapy in patients with mucopolysaccharidosis VI (Maroteaux–Lamy syndrome): a phase I/II study;Harmatz;Acta Paediatr. Suppl.,2005

5. Direct Comparison of Measures of Endurance, Mobility, and Joint Function During Enzyme-Replacement Therapy of Mucopolysaccharidosis VI (Maroteaux-Lamy Syndrome): Results After 48 Weeks in a Phase 2 Open-Label Clinical Study of Recombinant Human N-Acetylgalactosamine 4-Sulfatase

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biomarkers of Glycosaminoglycans (GAG) accumulation in patients with mucopolysaccharidosis type VI—LeukoGAG, Corneal Opacification (COM) and Carotid Intima Media Thickening (CIMT);Molecular Genetics and Metabolism Reports;2024-03

2. Current and Emerging Therapies for Mucopolysaccharidoses;Handbook of Experimental Pharmacology;2019

3. Innovative Treatments for Mucopolysaccharidoses;Journal of Child Science;2018-01

4. Mucopolysaccharidosis Type VI in a Great Dane Caused by a Nonsense Mutation in the ARSB Gene;Veterinary Pathology;2017-11-20

5. Disease models for the development of therapies for lysosomal storage diseases;Annals of the New York Academy of Sciences;2016-05